Literature DB >> 30894298

National acromegaly registries.

Luigi Maione1, Philippe Chanson2.   

Abstract

Acromegaly is a rare disease, associated with multiple organs and systems damage. Thanks to implementation of registries, systematic data gathering, knowledge sharing and standardizing medical practices for optimal care greatly improved. Data concerning 19 national acromegaly registries are available, involving more than 16,000 patients. The weighted mean age of diagnosis is 45.2 years and seems stable over time. A macroadenoma is found in 75% of the cases. The proportion of patients operated (>80%) did not change along time. By contrast, use of radiotherapy has decreased while use of medical therapy increased. If judged on IGF-I levels, acromegaly is controlled in 61.3% of the patients. The disease control rate has improved over time. This is likely due to the development of medical treatment strategies. The collection of data about comorbidities in national registries is much less comprehensive than those about epidemiology, disease control or treatment strategies. The most reported comorbidities are arterial hypertension and diabetes. Data concerning mortality trends are controversial. It seems that cancer has become a leading cause of death in acromegaly patients in the last decade, period in which life expectancy improved, while cardiovascular mortality decreased. In conclusion, acromegaly registries offer a global view of the disease with no "a priori" assumptions. This is of outmost importance, because of the large amount of data and the huge number of associated comorbidities. This will help to establish guidelines for management of this rare disease.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  acromegaly; epidemiology; mortality; registry

Mesh:

Substances:

Year:  2019        PMID: 30894298     DOI: 10.1016/j.beem.2019.02.001

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  10 in total

Review 1.  Electrophysiological features in acromegaly: re-thinking the arrhythmic risk?

Authors:  M Parolin; F Dassie; R Vettor; R P Steeds; P Maffei
Journal:  J Endocrinol Invest       Date:  2020-07-06       Impact factor: 4.256

2.  Evaluation of acromegaly treatment direct costs with respect to biochemical control and follow-up length.

Authors:  Francesco Cocchiara; Claudia Campana; Federica Nista; Giuliana Corica; Marco Ceraudo; Angelo Milioto; Diego Criminelli Rossi; Gianluigi Zona; Diego Ferone; Federico Gatto
Journal:  Pituitary       Date:  2021-11-10       Impact factor: 4.107

3.  Clinical Presentation, Treatment, and Outcome of Acromegaly in the United Arab Emirates.

Authors:  Khaled Al Dahmani; Bachar Afandi; Ali Elhouni; Denish Dinwal; Jim Philip; Alaaeldin Bashier; Salem A Beshyah; Nico Nagelkerke; Juma M Alkaabi
Journal:  Oman Med J       Date:  2020-09-20

4.  Characterization of the ability of a, second-generation SST-DA chimeric molecule, TBR-065, to suppress GH secretion from human GH-secreting adenoma cells.

Authors:  Thomas Cuny; Thomas Graillon; Célines Defilles; Rakesh Datta; Shengwen Zhang; Dominique Figarella-Branger; Henry Dufour; Grégory Mougel; Thierry Brue; Tanya Landsman; Heather A Halem; Michael D Culler; Anne Barlier; Alexandru Saveanu
Journal:  Pituitary       Date:  2021-01-12       Impact factor: 4.107

5.  Myokines in Acromegaly: An Altered Irisin Profile.

Authors:  Łukasz Mizera; Jowita Halupczok-Żyła; Katarzyna Kolačkov; Agnieszka Zembska; Jędrzej Grzegrzółka; Diana Jędrzejuk; Marek Bolanowski; Jacek Daroszewski
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-02       Impact factor: 5.555

6.  Acromegaly Initially Presenting with Severe Infectious Diseases: A Case Report.

Authors:  Eriko Tani; Tomonori Hirashima; Takamasa Hasegawa; Daisuke Aohara; Yuri Oshima; Yusuke Sakurai; Kaho Hirai; Naoki Yoshimoto; Mana Nishida; Yu Tateishi; Kenichi Minami
Journal:  JMA J       Date:  2021-12-24

7.  Factors associated with therapeutic response in acromegaly diagnosed in the elderly in Spain.

Authors:  Betina Biagetti; Pedro Iglesias; Rocío Villar-Taibo; María-Dolores Moure; Miguel Paja; Marta Araujo-Castro; Jessica Ares; Cristina Álvarez-Escola; Almudena Vicente; Èlia Álvarez Guivernau; Iria Novoa-Testa; Fernando Guerrero Perez; Rosa Cámara; Beatriz Lecumberri; Carlos García Gómez; Ignacio Bernabéu; Laura Manjón; Sonia Gaztambide; Fernando Cordido; Susan M Webb; Edelmiro Luis Menéndez-Torre; Juan J Díez; Rafael Simó; Manel Puig-Domingo
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-16       Impact factor: 6.055

8.  Clinical features and complications of acromegaly at diagnosis are not all the same: data from two large referral centers.

Authors:  Elena V Varlamov; Dan Alexandru Niculescu; Swechya Banskota; Simona Andreea Galoiu; Catalina Poiana; Maria Fleseriu
Journal:  Endocr Connect       Date:  2021-07-05       Impact factor: 3.335

Review 9.  Acromegaly: Clinical Care in Central and Eastern Europe, Israel, and Kazakhstan.

Authors:  Marek Bolanowski; Zaina Adnan; Mirjana Doknic; Mykola Guk; Václav Hána; Irena Ilovayskaya; Darko Kastelan; Tomaz Kocjan; Martin Kužma; Akmaral Nurbekova; Catalina Poiana; Nikolette Szücs; Silvia Vandeva; Roy Gomez; Sorin Paidac; Damien Simoneau; Ilan Shimon
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-22       Impact factor: 5.555

Review 10.  Genetics of Acromegaly and Gigantism.

Authors:  Anna Bogusławska; Márta Korbonits
Journal:  J Clin Med       Date:  2021-03-29       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.